Rasmus Holm-Jorgensen
Finanzdirektor/CFO bei ACRIVON THERAPEUTICS, INC.
Vermögen: 230 875 $ am 30.04.2024
Profil
Rasmus Holm-Jorgensen founded Kiniksa Pharmaceuticals Ltd.
in 2015, where he worked as Chief Strategy & Portfolio Officer from 2015 to 2022.
Mr. Holm-Jorgensen also currently works at Acrivon Therapeutics, Inc., as Chief Financial Officer from 2022.
Mr. Holm-Jorgensen also formerly worked at Synageva BioPharma Corp., as Group Vice President & General Manager from 2011 to 2015.
Mr. Holm-Jorgensen received his graduate degree from the University of Copenhagen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.05.2024 | 27 258 ( 0,09% ) | 230 875 $ | 30.04.2024 |
Aktive Positionen von Rasmus Holm-Jorgensen
| Unternehmen | Position | Beginn |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.04.2022 |
Ehemalige bekannte Positionen von Rasmus Holm-Jorgensen
| Unternehmen | Position | Ende |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Gründer | 01.04.2022 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01.01.2015 |
Ausbildung von Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
